|Dr. Michelle Miller BSc, MSc, Ph.D., GCertAppFin (Finsia)||CEO, MD & Exec. Director||N/A||N/A||N/A|
|Mr. Peter James Nightingale B.Econ, CA||Company Sec.||N/A||N/A||60|
|Dr. John Wilkinson Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viral diseases, such as dengue, zika, and influenza virus. Biotron Limited is based in North Ryde, Australia.
Biotron Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.